Transaction DateRecipientSharesTypePriceValue
20th November 2020Scott D Sandell69,564Open or private sale$67.27$4,679,507.67
20th November 2020Scott D Sandell97Open or private sale$65.64$6,367.08
19th November 2020Richard J Rodgers17,730Open or private purchase$0.00
19th November 2020Scott D Sandell267,743Open or private sale$65.84$17,626,913.95
18th November 2020Scott D Sandell51,428Open or private sale$65.53$3,369,871.13
17th November 2020Scott D Sandell312,171Open or private sale$65.62$20,484,879.54
16th November 2020Scott D Sandell86,980Open or private sale$64.24$5,587,751.76
13th November 2020Scott D Sandell20,578Other acquisition or disposition$0.00
13th November 2020Scott D Sandell165,945Other acquisition or disposition$0.00
13th November 2020Scott D Sandell2,500,000Other acquisition or disposition$0.00
Ardelyx
Ardelyx logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Ardelyx, Inc. focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.


Ticker: ARDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1437402
Employees: 88
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $100 M (0%)
Assets, Current: $212 M (-16%)
Property, Plant and Equipment, Net: $3 M (-27%)
Other Assets, Noncurrent: $271 Th (-13%)
Assets: $217 M (-16%)
Accounts Payable, Current: $4 M (92%)
Liabilities, Current: $34 M (51%)
Liabilities: $71 M (-2%)
Common Stock, Value, Issued: $9 Th (0%)
Common Stock, Shares, Issued: $89 M (0%)
Additional Paid in Capital, Common Stock: $654 M (1%)
Retained Earnings (Accumulated Deficit): $508 M (10%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $317 Th (1485%)
Stockholders' Equity (Parent): $146 M (0%)
Liabilities and Equity: $217 M (-16%)
Revenue: $2 M (-39%)
Research and Development: $19 M (-45%)
General and Administrative Expenses: $7 M (-50%)
Operating Income/Loss: $24 M (-47%)
Other Income, net: $477 Th (-61%)